Skip to main content Back to Top
Advertisement

12/1/2022

Rocuronium Injection

Products Affected - Description

    • Rocuronium Bromide solution for injection, Baxter, 10 mg/mL, 5 mL vial, 10 count, NDC 43066-0007-10
    • Rocuronium Bromide solution for injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 10 count, NDC 63323-0426-10
    • Rocuronium Bromide solution for injection, Fresenius Kabi, 10 mg/mL, 5 mL vial, 10 count, NDC 63323-0426-05
    • Rocuronium Bromide solution for injection, Hikma, 10 mg/mL, 10 mL vial, 10 count, NDC 00143-9251-10
    • Rocuronium Bromide solution for injection, Hikma, 10 mg/mL, 5 mL vial, 10 count, NDC 00143-9250-10
    • Rocuronium Bromide solution for injection, Pfizer, 10 mg/mL, 5 mL vial, 10 count, NDC 00409-9558-05
    • Rocuronium Bromide solution for injection, Piramal Critical Care, 10 mg/mL, 5 mL vial, 10 count, NDC 66794-0228-41
    • Rocuronium Bromide solution for injection, Sagent, 10 mg/mL, 10 mL vial, 10 count, NDC 25021-0662-10
    • Rocuronium Bromide solution for injection, Sagent, 10 mg/mL, 5 mL vial, 10 count, NDC 25021-0662-05
    • Rocuronium Bromide solution for injection, Sandoz, 10 mg/mL, 10 mL vial, 10 count, NDC 00781-3220-92
    • Rocuronium Bromide solution for injection, Sandoz, 10 mg/mL, 5 mL vial, 10 count, NDC 00781-3220-95

Reason for the Shortage

    • Athenex is no longer marketing rocuronium.
    • AuroMedics did not provide a reason for the shortage.
    • Baxter has rocuronium on shortage due to a third-party supplier issue.
    • Fresenius Kabi had rocuronium on shortage due to increased demand.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Pfizer has rocuronium on shortage due to increased demand.
    • Piramal Critical Care has rocuronium injection available.
    • Sagent has rocuronium injection available.
    • Sandoz did not provide a reason for the shortage.
    • X-Gen has rocuronium injection available.

Available Products

    • Rocuronium Bromide solution for injection, Baxter, 10 mg/mL, 10 mL vial, 10 count, NDC 43066-0013-10
    • Rocuronium Bromide solution for injection, Eugia US, 10 mg/mL, 10 mL vial, 10 count, NDC 55150-0226-10
    • Rocuronium Bromide solution for injection, Eugia US, 10 mg/mL, 5 mL vial, 10 count, NDC 55150-0225-05
    • Rocuronium Bromide solution for injection, Mylan Institutional (Viatris), 10 mg/mL, 10 mL vial, 10 count, NDC 67457-0228-10
    • Rocuronium Bromide solution for injection, Mylan Institutional (Viatris), 10 mg/mL, 5 mL vial, 10 count, NDC 67457-0228-05
    • Rocuronium Bromide solution for injection, Pfizer, 10 mg/mL, 10 mL vial, 10 count, NDC 00409-9558-10
    • Rocuronium Bromide solution for injection, Piramal Critical Care, 10 mg/mL, 10 mL vial, 10 count, NDC 66794-0229-41
    • Rocuronium Bromide solution for injection, X-Gen, 10 mg/mL, 10 mL vial, 10 count, NDC 39822-4200-06
    • Rocuronium Bromide solution for injection, X-Gen, 10 mg/mL, 5 mL vial, 10 count, NDC 39822-4200-02

Estimated Resupply Dates

    • Baxter has rocuronium 10 mg/mL 5 mL vials available in limited supply.
    • Fresenius Kabi has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of mid- to late-December 2022. There are short-dated 10 mL vials available for an expiration date of < 4 months.
    • Hikma has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of late-December 2022. The 10 mL vials are on allocation.
    • Pfizer has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of January 2023.
    • Sagent has rocuronium 10 mg/mL 5 mL vials on back order and the company estimates a release date of December 2022. There are short-dated 10 mL vials available with an expiration date of December 2022.

Updated

Updated December 1, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 9, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.